Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease

Trey Sunderland; Wade H. Berrettini; Susan E. Molchan; Brian A. Lawlor; Rick A. Martinez; Benedetto Vitiello; Pierre N. Tariot; Robert M. Cohen

doi:10.1016/0006-3223(91)90073-U

Reduced cerebrospinal fluid dynorphin A_1-8 in Alzheimer's disease

Trey Sunderland, Wade H. Berrettini, Susan E. Molchan, Brian A. Lawlor, Rick A. Martinez, Benedetto Vitiello, Pierre N. Tariot, Robert M. Cohen

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Cerebrospinal fluid (CSF) measures of dynorphin A_1-8 were compared in three groups. Alzheimer patients (n = 9), elderly depressives (n = 9), and age-matched normal controls (n = 9). The Alzheimer patients revealed a 40% decrease in CSF dynorphin compared with controls (36 ± 15 versus 60 ± 21 pg/ml. p < 0.05). In contrast other peptide measures [Neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and galanin] remained unchanged across groups. This finding was further supported when an additional 20 Alzheimer patients with similar clinical backgrounds also showed reduced CSF dynorphin (37 ± 13 pg/ml). CSF dynorphin did not correlate significantly with clinical variables or other CSF measures of monoamine metabolites [i.e., 3-methoxy-4-hydroxyphenylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA)]. Given the previous report of increased kappa binding of Alzheimer brains at autopsy, the authors speculate about a possible up-regulation of opiate receptors in Alzheimer's disease and suggest ways to test this hypothesis in vivo.

Original language	English (US)
Pages (from-to)	81-87
Number of pages	7
Journal	Biological psychiatry
Volume	30
Issue number	1
DOIs	https://doi.org/10.1016/0006-3223(91)90073-U
State	Published - Jul 1 1991
Externally published	Yes

ASJC Scopus subject areas

Biological Psychiatry

Access to Document

10.1016/0006-3223(91)90073-U

Cite this

@article{aa8edb8c9dd841bcb127b893b692a407,

title = "Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease",

abstract = "Cerebrospinal fluid (CSF) measures of dynorphin A1-8 were compared in three groups. Alzheimer patients (n = 9), elderly depressives (n = 9), and age-matched normal controls (n = 9). The Alzheimer patients revealed a 40% decrease in CSF dynorphin compared with controls (36 ± 15 versus 60 ± 21 pg/ml. p < 0.05). In contrast other peptide measures [Neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and galanin] remained unchanged across groups. This finding was further supported when an additional 20 Alzheimer patients with similar clinical backgrounds also showed reduced CSF dynorphin (37 ± 13 pg/ml). CSF dynorphin did not correlate significantly with clinical variables or other CSF measures of monoamine metabolites [i.e., 3-methoxy-4-hydroxyphenylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA)]. Given the previous report of increased kappa binding of Alzheimer brains at autopsy, the authors speculate about a possible up-regulation of opiate receptors in Alzheimer's disease and suggest ways to test this hypothesis in vivo.",

author = "Trey Sunderland and Berrettini, {Wade H.} and Molchan, {Susan E.} and Lawlor, {Brian A.} and Martinez, {Rick A.} and Benedetto Vitiello and Tariot, {Pierre N.} and Cohen, {Robert M.}",

year = "1991",

month = jul,

day = "1",

doi = "10.1016/0006-3223(91)90073-U",

language = "English (US)",

volume = "30",

pages = "81--87",

journal = "Biological psychiatry",

issn = "0006-3223",

publisher = "Elsevier USA",

number = "1",

}

TY - JOUR

T1 - Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease

AU - Sunderland, Trey

AU - Berrettini, Wade H.

AU - Molchan, Susan E.

AU - Lawlor, Brian A.

AU - Martinez, Rick A.

AU - Vitiello, Benedetto

AU - Tariot, Pierre N.

AU - Cohen, Robert M.

PY - 1991/7/1

Y1 - 1991/7/1

N2 - Cerebrospinal fluid (CSF) measures of dynorphin A1-8 were compared in three groups. Alzheimer patients (n = 9), elderly depressives (n = 9), and age-matched normal controls (n = 9). The Alzheimer patients revealed a 40% decrease in CSF dynorphin compared with controls (36 ± 15 versus 60 ± 21 pg/ml. p < 0.05). In contrast other peptide measures [Neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and galanin] remained unchanged across groups. This finding was further supported when an additional 20 Alzheimer patients with similar clinical backgrounds also showed reduced CSF dynorphin (37 ± 13 pg/ml). CSF dynorphin did not correlate significantly with clinical variables or other CSF measures of monoamine metabolites [i.e., 3-methoxy-4-hydroxyphenylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA)]. Given the previous report of increased kappa binding of Alzheimer brains at autopsy, the authors speculate about a possible up-regulation of opiate receptors in Alzheimer's disease and suggest ways to test this hypothesis in vivo.

AB - Cerebrospinal fluid (CSF) measures of dynorphin A1-8 were compared in three groups. Alzheimer patients (n = 9), elderly depressives (n = 9), and age-matched normal controls (n = 9). The Alzheimer patients revealed a 40% decrease in CSF dynorphin compared with controls (36 ± 15 versus 60 ± 21 pg/ml. p < 0.05). In contrast other peptide measures [Neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and galanin] remained unchanged across groups. This finding was further supported when an additional 20 Alzheimer patients with similar clinical backgrounds also showed reduced CSF dynorphin (37 ± 13 pg/ml). CSF dynorphin did not correlate significantly with clinical variables or other CSF measures of monoamine metabolites [i.e., 3-methoxy-4-hydroxyphenylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA)]. Given the previous report of increased kappa binding of Alzheimer brains at autopsy, the authors speculate about a possible up-regulation of opiate receptors in Alzheimer's disease and suggest ways to test this hypothesis in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0025738855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025738855&partnerID=8YFLogxK

U2 - 10.1016/0006-3223(91)90073-U

DO - 10.1016/0006-3223(91)90073-U

M3 - Article

C2 - 1716470

AN - SCOPUS:0025738855

SN - 0006-3223

VL - 30

SP - 81

EP - 87

JO - Biological psychiatry

JF - Biological psychiatry

IS - 1

ER -

Reduced cerebrospinal fluid dynorphin A_1-8 in Alzheimer's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this